Skip to main content

Table 1 Baseline clinical characteristics

From: Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma

Patient characteristic

DP group

(n = 103)

S-1 group

(n = 72)

p value

Age (median, year)

62

64

0.647

 < 60

48 (46.6%)

31 (43.1%)

 

 ≥ 60

55 (53.4%)

41 (56.9%)

 

Gender

  

0.873

Male

65 (63.1%)

47 (65.3%)

 

Female

38 (36.9%)

25 (34.7%)

 

KPS

  

0.756

90

43 (41.7%)

28 (38.9%)

 

 ≥ 70

60 (58.3%)

44 (61.1%)

 

Tumor location

  

0.394

Upper third

28 (27.2%)

16 (22.2%)

 

Middle third

60 (58.3%)

40 (55.6%)

 

Lower third

15 (14.5%)

16 (22.2%)

 

Primary tumor length (cm)

  

0.759

 < 5

56 (54.4%)

41 (56.9%)

 

 ≥ 5

47 (45.6%)

31 (43.1%)

 

Smoking

  

0.273

Nonsmoker

43 (41.7%)

24 (33.3%)

 

Smoker

60 (58.3%)

48 (66.7%)

 

Drinking

  

0.358

No

49 (47.6%)

29 (40.3%)

 

Yes

54 (52.4%)

43 (59.7%)

 

Differentiation

  

0.838

Well

14 (13.6%)

8 (11.1%)

 

Moderate

59 (57.3%)

44 (61.1%)

 

Poor

30 (29.1%)

20 (27.7%)

 

Clinical T stage

  

1.000

No invasion to adjacent organs

56 (54.4%)

39 (54.2%)

 

Invasion to adjacent organs

47 (45.6%)

33 (45.8%)

 

Clinical N stage

  

0.867

N0

30 (29.1%)

20 (27.8%)

 

N1

73 (70.9%)

52 (72.2%)

 

Reason for no surgery

  

0.924

Patient refusal

8 (7.7%)

6 (8.3%)

 

Surgical contraindication

15 (14.6%)

9 (12.5%)

 

Unresectable disease

65 (63.1%)

44 (61.1%)

 

Unknown

15 (14.6%)

13 (18.1%)

 

Radiation dose (Gy)

  

0.698

50

34 (33.0%)

23 (31.9%)

 

50.4

46 (44.7%)

29 (40.3%)

 

 > 50.4

23 (22.3%)

20 (27.8%)

 

Radiotherapy techniques

  

0.410

3D-CRT

30 (29.1%)

26 (36.1%)

 

IMRT

73 (70.9%)

46 (63.9%)

 

Consolidation chemotherapy

  

0.537

Yes

61 (59.2%)

39 (54.2%)

 

No

42 (40.8%)

33 (45.8%)

 

Nutritional support

  

0.265

Yes

17 (16.5%)

7 (9.7%)

 

No

86 (83.5%)

65 (90.3%)

 
  1. KPS Karnofsky performance status, 3D-CRT three-dimensional conformal radiotherapy, IMRT intensity modulated radiotherapy